• Procainamide Hydrochloride: From Electrophysiology to Epigen

  2026-05-12

  This in-depth thought-leadership article explores the evolving role of Procainamide Hydrochloride as both a cardiac sodium channel blocker and an epigenetic modulator, offering translational researchers mechanistic insights, evidence-led protocol recommendations, and strategic guidance for leveraging its dual-action profile. Building on recent advances in tumor immunology and workflow integration, we examine how this molecule bridges cardiac and oncology research, all while maintaining rigorous scientific credibility and practical utility.

• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-05-12

  This study employed structure-based virtual screening of natural products to identify potent inhibitors of the SARS-CoV-2 NSP15 endoribonuclease, revealing thymopentin and oleuropein as promising leads. The findings illuminate new avenues for antiviral research and underscore the importance of targeting NSP15 in viral immune evasion.

• Sodium Ascorbate: Mechanism, Evidence, and Cancer Research U

  2026-05-11

  Sodium Ascorbate, a mineral salt of ascorbic acid, demonstrates robust induction of intracellular ROS and necrotic tumor cell death in preclinical cancer models. Its unique solubility and bioavailability profile make it a preferred tool in glioblastoma multiforme research. This article provides a fact-based, structured overview with verifiable citations.

• Metformin HCl Inhibits Tendon Ossification via Nr4a1/Wnt/β-c

  2026-05-11

  This study demonstrates that Metformin Hydrochloride (Metformin HCl) markedly reduces heterotopic ossification in mouse Achilles tendon models by downregulating the Nr4a1/Wnt/β-catenin signaling pathway. The findings reveal a novel molecular target for non-surgical intervention in pathological soft tissue ossification, with direct implications for metabolic and bone disorder research.

• Repurposing Novobiocin: In Vitro Activity Against SFTSV

  2026-05-10

  A recent study systematically screened FDA-approved drugs for antiviral activity against severe fever with thrombocytopenia syndrome virus (SFTSV). Novobiocin emerged as a promising aminocoumarin antibiotic with significant in vitro efficacy and minimal cytotoxicity, supporting its potential in antiviral compound screening and drug repurposing research.

• (S)-(+)-Dimethindene maleate for Selective M2 Receptor Antag

  2026-05-09

  (S)-(+)-Dimethindene maleate enables precise antagonism of the muscarinic M2 and histamine H1 receptors, supporting targeted studies in autonomic regulation and cardiovascular physiology. It is not intended for diagnostic, therapeutic, or clinical applications and should be reserved for controlled research use only.

• HPF: Enabling Precision hROS Detection for Translational Onc

  2026-05-08

  This thought-leadership article unpacks the pivotal role of HPF (hydroxyphenyl fluorescein) in advancing highly reactive oxygen species (hROS) detection within translational cancer research. By integrating mechanistic insights, practical protocols, and strategic guidance, it positions HPF not merely as a technical solution, but as a catalyst for innovation in multimodal phototherapy and oxidative stress biology.

• Cyclo (-RGDfC) in High-Throughput Tumor Targeting: Stability

  2026-05-08

  Explore how Cyclo (-RGDfC) advances tumor targeting and angiogenesis research through unmatched integrin αvβ3 specificity and robust stability. This article uniquely connects peptide design with high-throughput assay innovation, offering practical guidance for next-generation cancer research.

• HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody: Protoco

  2026-05-07

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody enables sensitive, specific detection of rabbit primary antibodies in fluorescence-based assays, solving common challenges in signal amplification and background minimization. It is best used in immunofluorescence, immunocytochemistry, and flow cytometry where robust and reproducible detection of rabbit IgG is required. This reagent is not suitable for protocols targeting non-rabbit primaries or applications incompatible with sodium azide.

• Refining In Vitro Drug Evaluation in Cancer: Insights and To

  2026-05-07

  Schwartz's dissertation introduces a critical distinction between relative and fractional viability in assessing anti-cancer drug responses in vitro. This nuanced approach reveals that most drugs impact both cell proliferation and cell death, but in varying proportions and temporal patterns, advancing the rigor of preclinical drug evaluation.

• Myriocin Counteracts dAGE-Induced Metabolic Disruption in Mi

  2026-05-06

  This study demonstrates that myriocin, a sphingolipid synthesis inhibitor, robustly restores metabolic homeostasis in mice exposed to high dietary advanced glycation end products (dAGEs). Through targeted activation of the AMPK-PGC1α pathway, myriocin reverses obesity-related metabolic dysfunction, offering mechanistic insight and translational promise for addressing dAGE-driven metabolic syndrome.

• AG-120 (Ivosidenib): Mutant IDH1 Inhibition and 2-HG Reducti

  2026-05-06

  AG-120 (Ivosidenib) is a selective, orally bioavailable inhibitor targeting mutant IDH1. This article details its biochemical mechanism, evidence for 2-hydroxyglutarate reduction, and its application in AML research. Emphasis is placed on protocol parameters and current clinical limits.

• Mutant-Specific Activation of p53Y220C via TRAP-1: Mechanism

  2026-05-05

  The referenced study details the discovery of TRAP-1, a mutant-specific small molecule that reactivates p53Y220C by inducing proximity with BRD4, restoring transcriptional activity in cancer cells. These findings highlight a novel paradigm for therapeutic restoration of tumor suppressor function and present methodological advances with implications for precision oncology.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus: Techni

  2026-05-05

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus enables robust, high-yield synthesis of fluorescently labeled RNA probes for sensitive detection applications such as in situ hybridization and Northern blotting. It is designed solely for research workflows and should not be used in diagnostics or clinical protocols.

• Y-27632: Advanced Insights into ROCK Inhibition and Ribosome

  2026-05-04

  Explore Y-27632 as a selective ROCK inhibitor in the context of cytoskeletal dynamics and cancer cell ribosome stress. This article uniquely connects ROCK pathway modulation to emerging findings in ribosome biogenesis, offering researchers new, actionable perspectives.

15198 records 1/1014 page Next 12345 下5页 Last page